HONG KONG – China's health care sector is seeing a surge of mergers and acquisitions thanks to regulatory reforms that are expected to drive development. Case in point is Sciclone Pharmaceuticals Inc., a San Francisco-based drug developer that markets drugs in China. The company confirmed this month that it received an unsolicited $570 million acquisition offer.